Dr. Reddy's Laboratories

Dr. Reddy's Laboratories is an integrated global pharmaceutical enterprise operating across four main business segments: Generics (branded, unbranded, and biosimilars), API & Services (development, manufacturing, and research support), Innovative Medicines, and Consumer Health solutions.

Core Capabilities

The company provides comprehensive API and services including development, manufacturing, and research support. Dr. Reddy's has demonstrated expertise in:

• Biologics Manufacturing: Biosimilar development and manufacturing (rituximab, bevacizumab), CAR T-cell therapy for relapsed/refractory multiple myeloma, and recombinant protein manufacturing
• Small Molecule Development: Targeted cancer drugs (imatinib), innovative therapeutics (loxoprofen, colozo)
• Formulation & Process Development: Complex injectables and oral dosage forms
• Regulatory & CMC Support: Active US ANDAs, DMFs, and EU dossiers

Therapeutic Focus

The organization serves multiple therapeutic areas including oncology (immuno-oncology, CAR-T), infectious disease (HIV treatment via Lenacapavir partnership with Gilead), respiratory health (RSV protection via Beyfortus), gastroenterology, and women's health. Recent launches include India's first DCGI-approved semaglutide injection and oral semaglutide biosimilar.

Global Presence

With operations in 66 countries across Americas, Europe, Asia, Australia, and Africa, Dr. Reddy's maintains a distributed manufacturing and development footprint supporting both domestic and international markets.